Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Further strengthens BaseLaunch's global pharma industry partnerships
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subscribe To Our Newsletter & Stay Updated
